# US 2015/0148362 A1 · Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148362 A1
- Document ID: US20150148362A1
- Status: Published application
- Kind: A1
- Application number: 14/405,152
- Filed: 2013-06-04
- Published: 2015-05-28
- Earliest claimed: 2012-06-05
- Assignees: Korea University Research and Business Foundation
- Applicants: Korea University Research and Business Foundation
- Inventors: Won Ki Kim; Yongseok Choi; Sumi Song
- Web page: https://patentgrep.com/patent/US20150148362A1

## CPC

- C07C 49/86: containing —CHO groups
- A23L 29/055: {containing sulfur as heteroatom}
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/402: 1-aryl substituted, e.g. piretanide
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 49/798: containing rings other than six-membered aromatic rings
- C07C 49/813: polycyclic
- C07C 49/835: having unsaturation outside an aromatic ring
- C07D 207/02: with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D 213/50: Ketonic radicals
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- C07C 2602/42: the bicyclo ring system containing seven carbon atoms
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases.

## Claims

### Claim 1

A method of preventing or treating a degenerative brain disease by administering a pharmaceutical composition comprising a verbenone derivative represented by a following Formula 1 or a pharmaceutically acceptable salt thereof, as an active ingredient:
wherein R1, R2, R3, R4 and R5 are each independently at least one selected from the group consisting of a hydrogen atom, a halogen atom selected from F, Cl, Br and I, a hydroxyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, an amino group, a C1-C3 alkylamine group, a C1-C3 alkyldiamine group, a C5-C8 aromatic ring, a C5-C8 cyclic ring, and a C5-C8 heteroaromatic ring;
X, Y and Z are each independently a carbon atom or at least one heteroatom selected from the group consisting of N, O and S atoms; and
denotes a double bond or a single bond.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1, R2, R3, R4 and R5 are each independently at least one selected from the group consisting of a hydrogen atom, a halogen atom selected from F, Cl, Br and I, a hydroxyl group, a methyl group, an ethyl group, a methoxy group, an ethoxy group, an amino group, a C5-C6 aromatic ring, a C5-C6 cyclic ring, and a C5-C6 heteroaromatic ring.

### Claim 3 (depends on 2)

The method of claim 2, wherein R1, R2, R3, R4 and R5 are each independently at least one selected from the group consisting of a hydrogen atom, a halogen atom selected from F, Cl, Br and I, a hydroxyl group, a methyl group, a methoxy group, a phenyl group, a pyrrole group, and a pyridine group.

### Claim 4 (depends on 1)

The method of claim 1, wherein the X, Y and Z are each independently a carbon atom or at least one heteroatom selected from the group consisting of N, O and S atoms.

### Claim 5 (depends on 4)

The method of claim 4, wherein the X, Y and Z are each independently at least one atom selected from the group consisting of a carbon atom and an N atom.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises a compound selected from the group consisting of:
(1S,5R)-4-(4-hydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3a);
(1S,5R)-4-(4-hydroxy-2-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3b);
(1S,5R)-4-(3,4-dihydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3c);
(1S,5R)-4-(3-bromo-4-hydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3d);
(1S,5R)-4-(4-hydroxy-2,6-dimethoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3e);
(1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3f);
(1S,5R)-4-(3-hydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3g);
(1S,5R)-4-(2-hydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3h);
(1S,5R)-4-(2-hydroxy-4-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3i);
(1S,5R)-6,6-dimethyl-4-styryl-bicyclo[3.1.1]hept-3-en-2-one (4a);
(1S,5R)-4-(4-fluorostyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4b);
(1S,5R)-4-(4-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4c);
(1S,5R)-4-(2-(biphenyl-4-yl)vinyl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4d);
(1S,5R)-4-(4-(1H-pyrrol-1-yl)styryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4e);
(1S,5R)-4-(3,4-dimethoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (40;
(1S,5R)-4-(3,5-dimethoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4g);
(1S,5R)-4-(2,5-dimethoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4h);
(1S,5R)-4-(5-bromo-2-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4i);
(1S,5R)-6,6-dimethyl-4-((E)-2-(pyridin-2-yl)vinyl)-bicyclo[3.1.1]hept-3-en-2-one (5a);
(1S,5R)-6,6-dimethyl-4-((E)-2-(pyridin-3-yl)vinyl)-bicyclo[3.1.1]hept-3-en-2-one (5b); and
(1S,5R)-6,6-dimethyl-4-((E)-2-(pyridin-4-yl)-vinyl)-bicyclo[3.1.1]hept-3-en-2-one (5c).

### Claim 7 (depends on 1)

The method of claim 1, wherein the degenerative brain disease is stroke, palsy, dementia, Alzheimer's disease, Parkinson's disease, or Huntington's disease.

### Claim 8 (depends on 1)

The method of claim 1, wherein the degenerative brain disease is stroke.

### Claim 9

A method of preventing or improving a degenerative brain disease by administering health functional food comprising a verbenone derivative represented by a following Formula 1 or a pharmaceutically acceptable salt thereof, as an active ingredient:
wherein R1, R2, R3, R4 and R5 are each independently at least one selected from the group consisting of a hydrogen atom, a halogen atom selected from F, Cl, Br and I, a hydroxyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, an amino group, a C1-C3 alkylamine group, a C1-C3 alkyldiamine group, a C5-C8 aromatic ring, a C5-C8 cyclic ring, and a C5-C8 heteroaromatic ring;
X, Y and Z are each independently a carbon atom or at least one heteroatom selected from the group consisting of N, O and S atoms; and
denotes a double bond or a single bond.

### Claim 10 (depends on 9)

The method of claim 9, wherein R1, R2, R3, R4 and R5 are each independently at least one selected from the group consisting of a hydrogen atom, a halogen atom selected from F, Cl, Br and I, a hydroxyl group, a methyl group, an ethyl group, a methoxy group, an ethoxy group, an amino group, a C5-C6 aromatic ring, a C5-C6 cyclic ring, and a C5-C6 heteroaromatic ring.

### Claim 11 (depends on 10)

The method of claim 10, wherein R1, R2, R3, R4 and R5 are each independently at least one selected from the group consisting of a hydrogen, a halogen atom selected from F, Cl, Br and I, a hydroxyl group, a methyl group, a methoxy group, a phenyl group, a pyrrole group, and a pyridine group.

### Claim 12 (depends on 9)

The method of claim 9, wherein the X, Y and Z are each independently a carbon atom or at least one heteroatom selected from the group consisting of N, O and S atoms.

### Claim 13 (depends on 12)

The method of claim 12, wherein the X, Y and Z are each independently at least one atom selected from the group consisting of a carbon atom and an N atom.

### Claim 14 (depends on 9)

The method of claim 9, wherein the composition comprises a compound selected from the group consisting of:
(1S,5R)-4-(4-hydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3a);
(1S,5R)-4-(4-hydroxy-2-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3b);
(1S,5R)-4-(3,4-dihydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3c);
(1S,5R)-4-(3-Bromo-4-hydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3d);
(1S,5R)-4-(4-hydroxy-2,6-dimethoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3e);
(1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3f);
(1S,5R)-4-(3-hydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3g);
(1S,5R)-4-(2-hydroxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3h);
(1S,5R)-4-(2-hydroxy-4-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (3i);
(1S,5R)-6,6-dimethyl-4-styryl-bicyclo[3.1.1]hept-3-en-2-one (4a);
(1S,5R)-4-(4-fluorostyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4b);
(1S,5R)-4-(4-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4c);
(1S,5R)-4-(2-(biphenyl-4-yl)vinyl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4d);
(1S,5R)-4-(4-(1H-pyrrol-1-yl)styryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4e);
(1S,5R)-4-(3,4-dimethoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (40;
(1S,5R)-4-(3,5-dimethoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4g);
(1S,5R)-4-(2,5-dimethoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one (4h);
(1S,5R)-4-(5-bromo-2-methoxystyryl)-6,6-dimethyl bicyclo[3.1.1]hept-3-en-2-one (4i);
(1S,5R)-6,6-dimethyl-4-((E)-2-(pyridin-2-yl)vinyl)-bicyclo[3.1.1]hept-3-en-2-one (5a);
(1S,5R)-6,6-dimethyl-4-((E)-2-(pyridin-3-yl)vinyl)-bicyclo[3.1.1]hept-3-en-2-one (5b); and
(1S,5R)-6,6-dimethyl-4-((E)-2-(pyridin-4-yl)-vinyl)-bicyclo[3.1.1]hept-3-en-2-one (5c).

### Claim 15 (depends on 9)

The method of claim 9, wherein the degenerative brain disease is stroke, palsy, dementia, Alzheimer's disease, Parkinson's disease, or Huntington's disease.

### Claim 16 (depends on 15)

The method of claim 15, wherein the degenerative brain disease is stroke.
